One research group examined the effects of the AIP on IBD disease activity, quality of life, and gene expression (which measures the extent to which a cell is using information in its DNA to carry out certain processes) in the inner lining of the intestines. In that open-label, uncontrolled study, 18 adults with active ulcerative colitis or Crohn’s disease followed a 6-week elimination phase and subsequent 5-week maintenance phase (but no foods were reintroduced).
Out of the 14 participants who completed the intervention, 11 achieved clinical remission by the sixth week and sustained it through the maintenance phase. Though C-reactive protein (a marker of inflammation) and faecal calprotectin (a marker of intestinal damage) were elevated in some participants at the beginning of the study and lower after the intervention, those changes were not statistically significant. Two participants experienced worsening symptoms, and only about two-thirds of the participants actually adhered to the diet. [1]
Participants also completed quality-of-life questionnaires every 2 weeks, from baseline to the final week, but survey responses dwindled rapidly from 13 participants at baseline to only 4 at weeks 9 and 11. Average quality-of-life scores increased, and participants reported improvements in bowel movement frequency, stress, and ability to perform leisure activities. [2]
Researchers also measured gene expression in the mucosal lining of the intestines and found that some genes increased or decreased compared with baseline numbers. They interpreted this as a potential sign of mucosal healing, but it wasn’t explored further.
In an open-label, uncontrolled pilot study, 17 women with Hashimoto’s thyroiditis participated in a 10-week online coaching program on the AIP diet. Quality of life, clinical symptom burden (both the severity of symptoms and the perceived impact on the client’s life), and blood markers were assessed at baseline and after the intervention. Quality of life and symptom scores improved. C-reactive protein values and white blood cell count were lower after the intervention, but they were always within normal ranges. Although no markers of thyroid function or thyroid antibodies changed over the course of the program, 6 of the 13 women who had been using a thyroid medication reduced their dose after the program. Weight and body mass index (BMI) were significantly lower after the study, but based on the lack of change in thyroid markers, it’s unlikely that this was caused by a change in thyroid function. Notably, in their conflict of interest statement, the authors disclosed that they are the co-founders of the company that provided coaching for the participants in this study. [3]
Limited, low quality evidence suggests that quality of life and IBD disease activity may improve on the AIP, but it doesn't affect markers of thyroid function.